Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors

Annual Review of Medicine · Published 2023-09-27 · DOI 10.1146/annurev-med-071322-065903

Authors being retrieved — see the publisher record. https://doi.org/10.1146/annurev-med-071322-065903

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2023

Related articles

• Efficacy and safety of TROP2 antibody-drug conjugate-containing regimen in the patients with HER2 negative metastatic breast cancer and advanced non-small-cell lung cancer · JOURNAL OF CHEMOTHERAPY · 2026 · Cites or is cited by this article
• New Oral Selective Estrogen Receptor Degraders Redefine Management of Estrogen Receptor–Positive Breast Cancer · Annual Review of Medicine · 2025 · Same journal
• CD70: An Emerging Anticancer Target in Renal Cell Carcinoma and Beyond · Annual Review of Medicine · 2024 · Same journal
• Emerging Long-Term Risks of the Use of Proton Pump Inhibitors and Potassium-Competitive Acid Blockers · Annual Review of Medicine · 2024 · Same journal
• Biologic Medications for Severe Asthma: Implications for Understanding Pathogenic Heterogeneity and Endotypes · Annual Review of Medicine · 2024 · Same journal
• Lessons from the Use of Monoclonal Antibodies to SARS-CoV-2 Spike Protein During the COVID-19 Pandemic · Annual Review of Medicine · 2024 · Same journal
• Advances in Therapy for Refractory Epilepsy · Annual Review of Medicine · 2024 · Same journal
• Approach to Therapy for Chronic Pouchitis · Annual Review of Medicine · 2025 · Same journal
• Cancer Neoantigen Vaccines Emerge Efficacious · Annual Review of Medicine · 2026 · Same journal
• Lipoprotein(a): An Underappreciated Inherited Risk Factor for Atherosclerosis, Aortic Stenosis, and Abdominal Aortic Aneurysm · Annual Review of Medicine · 2025 · Same journal